Avoiding unnecessary intraoperative sentinel lymph node frozen section biopsy of patients with early breast cancer

Jongwon Kang1, Tae-Kyung Yoo2,*, Ahwon Lee3,*, Jun Kang1, Chang Ik Yoon1, Bong Joo Kang1, Sung Hun Kim4, Woo Chan Park1

1Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
2Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
3Department of Hospital Pathology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
4Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

INTRODUCTION

Axillary lymph node (ALN) metastasis is one of the most important prognostic factors for early breast cancer patients. Axillary management, which has evolved from ALN dissection (ALND) to sentinel lymph node (SLN) biopsy is essential for axillary staging and reducing surgical morbidity without compromising oncological safety. Frozen section biopsy is

Purpose: After the publication of the ACOSOG (American College of Surgeons Oncology Group) Z0011 trial, the rate of axillary lymph node dissection has reduced. Thus, the need for intraoperative frozen section biopsy of sentinel lymph nodes (SLNs) has become controversial. We identified patients for whom intraoperative SLN frozen section biopsy could be omitted and found that frozen section biopsy rate can be reduced.

Methods: We reviewed the records of patients with tumors ≤5 cm in diameter who underwent breast-conserving surgery between January 2013 and December 2019 at Seoul St. Mary’s Hospital. Clinicopathological and imaging characteristics were compared according to number of positive SLNs (0–2 SLNs positive vs. ≥3 SLNs positive).

Results: A total of 1,983 patients were included in this study. Thirty-two patients (1.6%) had at least 3 positive SLNs. Patients with ≥3 positive SLNs had significantly larger tumors and were more frequently high-grade tumors (P < 0.001 and P = 0.002, respectively). Identification of suspicious lymph nodes on imaging studies was also associated with the presence of ≥3 positive SLNs (hazard ratio, 11.54; 95% confidence interval, 4.42–30.10). All patients with none or only 1 suspicious lymph node on any imaging modality (n = 647, 32.6%) had 0–2 positive SLNs. Also, among patients with clinical T1-stage tumors and at least 2 suspicious lymph nodes on only 1 imaging modality (n = 514, 25.9%), only 2 cases had ≥3 positive SLNs.

Conclusion: We found that intraoperative SLN frozen biopsy could be omitted in patients using tumor size and axillary lymph node status on imaging modality.

Key Words: Breast neoplasms, Frozen sections biopsy, Magnetic resonance imaging, Sentinel lymph node
widespread use of SLN mapping reduced the need for a second operation when metastases are identified in SLNs.

Currently, the need for ALND has decreased because several clinical trials have established the safety of ALND omission in early breast cancer patients with minimal axillary involvement [1-3]. Breast cancer patients with clinical T1–2 tumors, node-negative disease and those undergoing primary surgery are candidates for ALND omission. If patients’ evidence micrometastases or only 1 or 2 metastatic SLNs, ALND can be omitted without compromising the oncological outcomes. Since the publication of these studies, the ALND rate has markedly decreased worldwide [4,5]. This raises the question of whether intraoperative SLN frozen section biopsy is required. Frozen section biopsy exhibits low sensitivity in terms of micrometastasis detection and is associated with a risk of permanent tissue loss; it prolongs the operation time and increases medical costs. Hence, we aimed to identify preoperative status which affects SLNs positivity and patients for whom SLN frozen section biopsy can be omitted without increasing the risk of second operation for ALND.

METHODS

The study was approved by the Institutional Review Board of Seoul St. Mary’s Hospital (No. KC21RISI0774); the need to obtain informed patient consent was waived.

Patients who underwent breast cancer surgery from January 2013 to December 2019 at Seoul St. Mary’s Hospital were considered eligible. Patients with clinical stage T1–2 tumors who underwent breast-conserving surgery were reviewed retrospectively. Using the criteria of the ACOSOG (American College of Surgeons Oncology Group) Z0011 trial, patients who underwent total mastectomy or neoadjuvant chemotherapy, or those who initially underwent axillary surgery, or who were diagnosed preoperatively with ALN phyllodes tumor, occult breast cancer, or local recurrence and metastasis or internal mammary lymph node metastasis, were also excluded. Patients who underwent initial surgery in other hospitals were excluded as clinical tumor size data was missing.

Every case was evaluated in terms of clinicopathological factors as well as by breast ultrasonography, mammography, breast MRI, and PET/CT or chest CT. In mid-2017, the health insurance policy of the Republic of Korea stopped covering PET/CT and was replaced with chest CT; therefore, we combined PET/CT and CT data in the present study. We did not include physical examination data because of incomplete medical records.

Axillary imaging results were extracted from the radiology reports of board-certified breast radiologists. We used the breast imaging-reporting and data system (BI-RADS) to evaluate ultrasonographic, mammographic, and MRI data. An ALN was considered suspicious if it exhibited eccentric cortical thickening, a round shape, or absence of fatty hilum [6]. An ALN with ¹⁸F-fluorodeoxyglucose uptake observed by PET/CT was defined as a suspicious ALN [7]. The axillary imaging results were divided into 3 categories according to the number of suspicious lymph nodes: no suspicious ALN, 1 suspicious ALN, and at least 2 suspicious ALNs.

The clinical tumor size, tumor location, and multifocality status were determined by breast MRI, but we used ultrasound data when MRI results were lacking. Pathological parameters (histological subtype, tumor grade, hormone receptor status, and human epidermal growth factor receptor [HER2] and Ki67 status) were obtained from pathological analyses of surgical specimens. Commencing in mid-2017, ALND omission as recommended by the ACOSOG Z0011 and IBCSG (International Breast Cancer Study Group) 23-01 trials was partially performed. We divided patients into 2 groups: 0–2 positive SLNs group and ≥3 positive SLNs group, to compare patients that could omit ALND to patients who should perform ALND. Clinicopathologic factors were also compared according to number of metastatic ALNs to explore whether factors related to positive SLNs sustained in these groups too.

Univariate analysis was performed using the Pearson chi-square test. Student t-test, and logistic regression analysis, as appropriate. Statistical significance was defined as a P-value of <0.05. All statistical analyses were conducted using IBM SPSS Statistics ver. 23.0 (IBM Corp., Armonk, NY, USA). Variables are presented as numbers with percentages.

RESULTS

A total of 4,301 patients underwent breast cancer surgery at Seoul St. Mary’s Hospital from January 2013 to December 2019 (Fig. 1). After applying the exclusion criteria, 1,983 cases were included, among which 11 were bilateral breast cancer cases. The median patient age was 52 years (range, 14–88 years). More than 60% of cases had a clinical T1 tumor and the majority (n = 1,680, 84.7%) were invasive ductal carcinoma. ALND omission was performed in 187 cases (9.4%). The study cohort was divided into 2 groups according to SLN metastasis status: patients with less than 3 positive SLNs (0–2 positive SLNs) and those with at least 3 positive SLNs (≥3 positive SLNs). Thirty-two patients (1.6%) had ≥3 positive SLNs. The 2 groups were compared in terms of clinicopathological factors and radiological findings (Table 1). Patients with ≥3 positive SLNs exhibited significantly larger tumors on preoperative MRI (P < 0.001), but age, multifocality, and tumor location did not affect the number of positive SLNs. High-grade tumors were more
Table 1. Clinicopathological characteristics associated with number of positive SLNs

| Characteristic                  | 0–2 Positive SLNs | ≥3 Positive SLNs | P-value |
|--------------------------------|-------------------|------------------|---------|
| No. of patients                | 1,951             | 32               |         |
| Age (yr)                       | 53.23±10.88       | 51.63±11.39      | 0.409   |
| <50                            | 858 (44.0)        | 15 (46.9)        | 0.858   |
| ≥50                            | 1,093 (56.0)      | 17 (53.1)        |         |
| Diagnosis method               |                   |                  |         |
| Core needle biopsy             | 1,862 (95.4)      | 31 (96.9)        | 0.356   |
| Excision                       | 89 (4.6)          | 1 (3.1)          |         |
| Tumor size (cm)                | 1.62±0.87         | 2.44±0.60        | <0.001  |
| ≤2                             | 1,419 (72.7)      | 7 (21.9)         | <0.001  |
| >2, ≤5                         | 532 (27.3)        | 25 (78.1)        |         |
| Multifocality by MRI           |                   |                  |         |
| Unifocal                       | 453 (23.2)        | 10 (31.3)        | 0.441   |
| Multifocal                     | 1,448 (74.2)      | 22 (68.8)        |         |
| Unknown                        | 50 (2.6)          | 0 (0)            |         |
| Tumor location                 |                   |                  |         |
| Upper outer                    | 1,074 (55.0)      | 22 (68.8)        | 0.345   |
| Lower outer                    | 242 (12.4)        | 5 (15.6)         |         |
| Central                        | 75 (3.8)          | 1 (3.1)          |         |
| Upper inner                    | 461 (23.6)        | 3 (9.4)          |         |
| Lower inner                    | 99 (5.1)          | 1 (3.1)          |         |
| Histologic subtype             |                   |                  |         |
| IDCa                           | 1,624 (83.2)      | 30 (93.8)        | 0.213   |
| ILCa                           | 98 (5.0)          | 2 (6.3)          |         |
| Tubular, mucinous              | 91 (4.7)          | 0 (0)            |         |
| Others                         | 138 (7.1)         | 0 (0)            |         |
| Histologic grade               |                   |                  |         |
| Low<sup>a</sup>               | 1,379 (70.7)      | 15 (46.9)        | 0.008   |
| High<sup>b</sup>              | 529 (27.1)        | 17 (53.1)        |         |
| Unknown                        | 43 (2.2)          | 0 (0)            |         |
| ER and/or PR                   |                   |                  |         |
| Positive                       | 1,567 (80.3)      | 25 (78.1)        | 0.822   |
| Negative                       | 384 (19.7)        | 7 (21.9)         |         |

Fig. 1. Flowchart of the patients. ALND, axillary lymph node dissection; ALN, axillary lymph node; SLN, sentinel lymph node.
frequent in patients with ≥3 positive SLNs (P = 0.008), but histological subtype, hormone receptor status, HER2 status, and Ki67 were not associated with nodal status. The results were generally similar when patients were analyzed according to ALN metastasis status, with the exception that tumor location affected the ALN metastasis status (Supplementary Table 1). Patients with at least 3 positive ALNs had a higher rate of upper, outer quadrant tumors compared with those with less than 3 positive ALNs (P = 0.011).

The radiological findings were categorized according to the

Table 1.

| Characteristic | No. of positive SLNs | P-value |
|----------------|----------------------|---------|
| | 0–2 | ≥3 |
| HER2 | | |
| Positive | 241 (12.4) | 5 (15.6) | 0.865 |
| Negative | 1,688 (86.5) | 27 (84.4) | |
| Equivocal | 22 (1.1) | 0 (0) | |
| Ki67 (%) | | |
| <25 | 1,022 (52.4) | 11 (34.4) | 0.080 |
| ≥25 | 929 (47.6) | 21 (65.6) | |
| Mammography | | |
| No suspicious ALN | 1,649 (84.5) | 15 (46.9) | <0.001 |
| Only 1 suspicious ALN | 79 (4.0) | 4 (12.5) | |
| >1 Suspicious ALN | 112 (5.7) | 11 (34.4) | |
| Unknown | 111 (5.7) | 2 (6.2) | |
| Ultrasound | | |
| No suspicious ALN | 1,114 (57.1) | 4 (12.5) | <0.001 |
| Only 1 suspicious ALN | 229 (11.7) | 6 (18.8) | |
| >1 Suspicious ALN | 503 (25.8) | 20 (62.5) | |
| Unknown | 105 (5.4) | 2 (6.3) | |
| MRI | | |
| No suspicious ALN | 783 (40.1) | 0 (0) | <0.001 |
| Only 1 suspicious ALN | 171 (8.8) | 1 (3.1) | |
| >1 Suspicious ALN | 971 (49.8) | 29 (90.6) | |
| Unknown | 26 (1.3) | 2 (6.3) | |
| PET-CT or chest CT | | |
| No suspicious ALN | 1,144 (58.6) | 8 (25.0) | 0.001 |
| Only 1 suspicious ALN | 137 (7.0) | 4 (12.5) | |
| >1 Suspicious ALN | 570 (29.2) | 18 (56.3) | |
| Unknown | 100 (5.1) | 2 (6.3) | |

Table 2. Radiologic findings of suspicious LNs by number of positive SLNs

| Radiologic finding | No. of positive SLNs | P-value |
|--------------------|----------------------|---------|
| | 0–2 | ≥3 |
| All negative | 528 (27.1) | 0 (0) | <0.001 |
| Only 1 suspicious LN | | | |
| Only 1 image with >1 suspicious LN | 682 (35.0) | 5 (15.6) | |
| 2 Or more images with >1 suspicious LN | 622 (31.9) | 27 (84.4) | |

Values are presented as number only, mean ± standard deviation, or number (%). SLN, sentinel lymph node; IDCa, invasive ductal carcinoma; ILCa, invasive lobular carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; ALN, axillary lymph node.

*Grade 1 and 2, "grade 3.

Values are presented as number only, mean ± standard deviation, or number (%). SLN, sentinel lymph node; SLN, sentinel lymph node.

*No evidence of suspicious axillary LN in all image tests. "Only 1 suspicious axillary LN in all image tests. "Two or more suspicious axillary LNs in only 1 image test. "Two or more suspicious axillary LNs in more than 1 image tests.
number of suspicious ALNs revealed by the various imaging modalities. The number of suspicious ALNs was significantly related to the number of positive SLNs regardless of the imaging modality used (all P < 0.001). Notably, when MRI revealed no suspicious ALNs, no case had more than 2 positive SLNs. The radiological findings were also categorized according to the number of imaging modalities revealing several suspicious ALNs (Table 2). All cases that were negative for ALNs on imaging studies (n = 528, 27.1%) or had only 1 suspicious ALN on all imaging modalities (n = 119, 6.1%) had 0–2 positive SLNs.

On univariate logistic regression analysis, larger tumor size, 2 or more suspicious ALNs on a single-image test result, and 2 or more suspicious ALNs on multi-imaging modalities were associated with at least 3 positive SLNs group (Table 3).

Patients who exhibited none or only 1 suspicious ALN on any imaging modality (n = 647, 32.6%) did not require intraoperative SLN frozen section biopsy. Only 2 cases (0.4%) had more than 2 positive SLNs. Thus, if intraoperative SLN frozen section biopsy is omitted in these cases, 1,161 patients (58.5%) would not undergo unnecessary frozen section biopsy, and only 2 patients (0.1%) would require a second operation for ALND (Fig. 2).

**DISCUSSION**

The ALND rate has decreased after several clinical trials demonstrated the oncological safety of ALND omission in patients with limited axillary nodal burden. Thus, the need for intraoperative SLN evaluation has also decreased. Here, we sought clinicopathologic factors identifying patients who do not need SLN frozen section biopsy without any increase in the risk of a secondary operation featuring ALND. Both tumor size and axillary imaging status were strongly associated with axillary nodal status. The MRI results and the number of suspicious lymph nodes evident on imaging studies could be considered when the possibility of omitting SLN frozen section biopsy is raised.

The need for intraoperative SLN frozen section biopsy has been discussed in several studies [8-12]. Those studies focused principally on accuracy of frozen section biopsy, reporting a false-negative rate of 11.7%–13.6% [9,11,12]. Although micro-metastases greatly affect the false-negative rate, the IBCSG 23-01 trial found that micro-metastases are not an indication for additional ALND. The current role of intraoperative SLN frozen section biopsy remains controversial. In studies that actively omitted ALND (guided by the ACOSOG Z0011 trial data), the need for SLN frozen section biopsy was minimal [11,13]. However, studies that questioned the appropriateness of ALND omission argued the need for frozen section biopsy [8,9,11,14,15]. In this study, we sought to identify patients who could safely omit SLN frozen section biopsy. Various nomograms and predictive models guiding selective frozen section biopsy of SLNs have been proposed [16,17]. However, the included...
factors differed from this study. The nomogram of Ahn et al. [16] included axillary ultrasound and chest CT data and patient age. Our study also included preoperative imaging data, but additionally added MRI data that greatly reflected ALN burden in the study. Zeng et al. [17] developed a negative binomial regression model that included histological grade, estrogen receptor, and HER2 status, but lacked imaging data which was an important factor in this study. Contrary to previous studies, age and estrogen receptor/HER2 status did not affect the ALN metastatic burden in this study.

Imaging is essential in terms of axillary evaluation and estimation of the nodal burden. Ultrasound is useful for evaluating axillae and is performed in newly diagnosed breast cancer at many centers. MRI reveals the breast cancer extent and yields additional axillary data, including enhancement of potentially suspicious lymph nodes. MRI can be used to compare the 2 axillae and is less operator-dependent than ultrasound [18]. Moreover, MRI provides a global view of the axilla, which is increasingly relevant because the number of metastatic ALNs is more important than simply identifying metastasis. Notably, we found that the MRI results were strongly correlated with nodal burden. PET/CT is useful for evaluating the axillae and revealing metabolic activity. The diagnostic accuracies of PET/CT and MRI for axillary evaluation are comparable, but MRI affords a higher sensitivity when functional values are included [19,20].

This study had several limitations. This was a single-center retrospective study, and therefore selection bias may have been in play. We did not include physical examination data because the medical records lacked consistency; high-quality records were required when selecting patients for the ACOSOG Z0011 trial. Also, the tool used to evaluate disease extent changed from CT to PET/CT during the study period due to change of reimbursement policy. Additionally, although the 2 groups were homogeneous, the patient numbers differed considerably, which may have reduced the reliability of our results.

In conclusion, both preoperative imaging data of tumor size and ALNs status are important when predicting whether there will be more than 2 positive SLNs. SLN frozen section biopsy omission can be considered in patients with small tumors and minimally suspicious ALNs on imaging studies including breast MRI.

**SUPPLEMENTARY MATERIAL**

Supplementary Table 1 can be found via https://doi.org/10.4174/astr.2022.102.5.241.

**ACKNOWLEDGEMENT**

**Fund/Grant Support**
This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (grant No. 2021R1I1A01058328).

**Conflict of Interest**
No potential conflict of interest relevant to this article was reported.

**ORCID iD**
Jongwon Kang: https://orcid.org/0000-0002-9183-8655
Tae-Kyung Yoo: https://orcid.org/0000-0002-5790-353X
Ahwon Lee: https://orcid.org/0000-0002-2523-9531
Jun Kang: https://orcid.org/0000-0002-7967-0917
Chang Ik Yoon: https://orcid.org/0000-0002-7273-8886
Bong Joo Kang: https://orcid.org/0000-0002-5991-6035
Sung Hun Kim: https://orcid.org/0000-0003-4478-9720
Woo Chan Park: https://orcid.org/0000-0002-1265-1981

**Author Contribution**
Conceptualization: AL
Formal Analysis: Jongwon Kang, TKY
Investigation: TKY, Jun Kang, CIY, BJK, SHK
Methodology: WCP
Project Administration: TKY
Writing – Original Draft: Jongwon Kang, TKY
Writing – Review & Editing: All authors

**REFERENCES**

1. Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol 2014;15:1303-10.
2. Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013;14:297-305.
3. Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection
1. Tseng J, Alban RF, Siegel E, Chung A, Giuliano AE, Amersi FF. Changes in utilization of axillary dissection in women with invasive breast cancer and sentinel node metastasis after the ACOSOG Z0011 trial. Breast J 2021;27:216-21.

5. Poodt I, Spronk P, Vuugs G, van Dalen T, Peeters M, Rots ML, et al. Trends on axillary surgery in nondistant metastatic breast cancer patients treated between 2011 and 2015: a Dutch population-based study in the ACOSOG-Z0011 and AMAROS era. Ann Surg 2018;268:1084-90.

6. Kim EJ, Kim SH, Kang BJ, Choi BG, Song BJ, Choi JI. Diagnostic value of breast MRI for predicting metastatic axillary lymph nodes in breast cancer patients: diffusion-weighted MRI and conventional MRI. Magn Reson Imaging 2014;32:1230-6.

7. Choi WH, Yoo IR, O JH, Kim SH, Chung SK. The value of dual-time-point 18F-FDG PET/CT for identifying axillary lymph node metastasis in breast cancer patients. Br J Radiol 2011;84:593-9.

8. Bishop JA, Sun J, Ajkay N, Sanders MA. Decline in frozen section diagnosis for axillary sentinel lymph nodes as a result of the American College of Surgeons Oncology Group Z0011 trial. Arch Pathol Lab Med 2016;140:830-5.

9. Cipolla C, Graceffa G, Cabibi D, Gangi G, Latteri M, Valerio MR, et al. Current role of intraoperative frozen section examination of sentinel lymph node in early breast cancer. Anticancer Res 2020;40:1711-7.

10. Jorns JM, Kidwell KM. Sentinel lymph node frozen-section utilization declines after publication of American College of Surgeons Oncology Group Z0011 trial results with no change in subsequent surgery for axillary lymph node dissection. Am J Clin Pathol 2016;146:57-66.

11. Lombardi A, Nigri G, Maggi S, Stanzani G, Vitale V, Vecchione A, et al. Role of frozen section in sentinel lymph node biopsy for breast cancer in the era of the ACOSOG Z0011 and IBCSG 23-10 trials. Surgeon 2018;16:232-6.

12. Yoon KH, Park S, Kim JY, Park HS, Kim SI, Cho YU, et al. Is the frozen section examination for sentinel lymph node necessary in early breast cancer patients? Ann Surg Treat Res 2019;97:251-8.

13. Jung SM, Woo J, Ryu JM, Lee SK, Chae BJ, Yu J, et al. Is the intraoperative frozen section analysis of sentinel lymph nodes necessary in clinically negative axillary breast cancer? Ann Surg Treat Res 2020;99:251-8.

14. Lai SK, Masir N, Md Pauzi SH. Intraoperative frozen section sentinel lymph node assessment in breast cancer: a tertiary institution experience. Malays J Pathol 2018;40:121-8.

15. Godazande G, Moradi S, Naghshvar F, Shojaei L. Is necessary intraoperative frozen section in sentinel lymph node biopsy for breast cancer patients? Asian Pac J Cancer Prev 2020;21:647-51.

16. Ahn SK, Kim MK, Kim J, Lee E, Yoo TK, Lee HB, et al. Can we skip intraoperative evaluation of sentinel lymph nodes? Nomogram predicting involvement of three or more axillary lymph nodes before breast cancer surgery. Cancer Res Treat 2017;49:1088-96.

17. Zeng D, Lin HY, Zhang YL, Wu JD, Lin K, Xu Y, et al. A negative binomial regression model for risk estimation of 0-2 axillary node metastases in breast cancer patients. Sci Rep 2020;10:21856.

18. Chang JM, Leung JW, Moy L, Ha SM, Moon WK. Axillary nodal evaluation in breast cancer: state of the art. Radiology 2020;295:500-15.

19. Zhang X, Liu Y, Luo H, Zhang J. PET/CT and MRI for identifying axillary lymph node metastases in breast cancer patients: systematic review and meta-analysis. J Magn Reson Imaging 2020;52:1840-51.

20. Liang X, Yu J, Wen B, Xie J, Cai Q, Yang Q. MRI and FDG-PET/CT based assessment of axillary lymph node metastasis in early breast cancer: a meta-analysis. Clin Radiol 2017;72:295-301.